Robotic SurgeryNCT07710352
Low Gas Pressure vs Standard Gas Pressure in Robotic Surgery
A study testing AirSeal Robotic Solution and Standard-pressure pneumoperitoneum (15 mmHg) in people with Robotic Surgery and Pneumoperitoneum, run by Weill Medical College of Cornell University at 1 site in United States.
Trial summary
During surgery that is done using a robot, the surgeon needs to put carbon dioxide gas into the belly to lift the belly wall. This is done so the surgeon can adequately see all the body organs and operate safely. Many surgeons currently use a standard pressure of 15 mmHg (a unit to measure pressure). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Robotic Surgery, Pneumoperitoneum
- What is being tested?
- AirSeal Robotic Solution and Standard-pressure pneumoperitoneum (15 mmHg)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteUnited States
- Study dates
- 30 Jul 2026to Feb 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged 18 years or older
- Scheduled to undergo robotic-assisted surgery at New York-Presbyterian/Weill Cornell Medical Center
- American Society of Anesthesiologists physical status I-III
- Able to understand and provide written informed consent in English
Who cannot join
- American Society of Anesthesiologists physical status IV or higher (i.e. a severe systemic disease that is a constant threat to life such as decompensated heart failure)
- Chronic opioid use (≥30 morphine milligram equivalents per day for ≥30 days within the past 6 months)
- Current pregnancy
- Inability to understand and provide informed consent in English
- Inability to provide informed consent due to cognitive impairment or other conditions impacting decision-making capacity
- Scheduled open or laparoscopic surgeries
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
New York-Presbyterian/Weill Cornell Medical Center GI Metabolic and Bariatric Surgery
New York, New York, 10021
Cheguevara Afaneh, MD, (646) 962-8462, cha9043@med.cornell.edu
Cheguevara Afaneh, MD
About this study
Official title: Comparison Between Low Pressure (8 mmHg) AirSeal Insufflation vs Standard Pressure (15 mmHg) Pneumoperitoneum on Postoperative Recovery in Minimally Invasive Robotic Surgery: A Randomized Controlled Trial
During surgery that is done using a robot, the surgeon needs to put carbon dioxide gas into the belly to lift the belly wall. This is done so the surgeon can adequately see all the body organs and operate safely. Many surgeons currently use a standard pressure of 15 mmHg (a unit to measure pressure). However, many patients find the use of this pressure to be painful after surgery. New research has shown that using a lower pressure with a device called "AirSeal" can safely reduce pain and lead to faster recovery after surgery.
The goal of this clinical trial is to learn if using a lower gas pressure with the AirSeal device during robotic surgery, compared to standard gas pressure with conventional devices, helps adults feel less pain and recover faster.
Read more
The study includes adults aged 18 or older having robotic at New York-Presbyterian Hospital/Weill Cornell Medical Center.
The main questions this clinical trial aims to answer are:
- Does using lower gas pressure shorten the time people spend in the recovery room after surgery?
- Does using lower gas pressure lead to less pain and reduce the need for pain medicine after surgery?
Read the detailed description
Robotic surgeries require the use of pneumoperitoneum, which is a standard of care as it creates a working environment to utilize minimally invasive tools to accomplish surgical procedures. However, there is no uniform standard pressure (usually between 12-15 mmHg). Moreover, maintaining the same pressure throughout the procedure can be inconsistent at best. Elevations in pneumoperitoneum cause significant stretch to the peritoneum which results in significant postoperative pain, longer post-anesthesia care unit (PACU) stay times, and higher opioid consumption. These effects are amplified to a higher degree in patients with severe obesity. If the pressures can be maintained and set to lower levels, then patients may have the opportunity to recover in the immediate postoperative period.
The AirSeal Robotic Solution (CONMED Corporation) is an FDA 510(k)-cleared carbon dioxide insufflation device that is indicated for use in robotic-assisted surgery.
This study is a prospective, single-center, single-blind, double-arm parallel-group randomized controlled trial that aims to determine if the use of low-pressure (8 mmHg) AirSeal insufflation, compared to standard-pressure (15 mmHg) pneumoperitoneum, provides superior patient outcomes in terms of post-operative recovery time and convalescence.
During the preoperative evaluation, participants will be consented and enrolled into the trial. Participants will then be randomly allocated to either low-pressure AirSeal insufflation (8 mmHg) or standard-pressure pneumoperitoneum (15 mmHg). Patients and outcome assessors will be blinded to allocation; however, for safety purposes, the operating surgeon and anesthesiologist cannot be blinded.
Intraoperative data (including operation time, estimated blood loss, abdominal pressure, and pressure deviations) will be recorded. Participant data related to comorbidities (i.e. body mass index, American Society of Anesthesiologists physical status, hypertension, diabetes, obstructive sleep apnea, chronic obstructive pulmonary disease/asthma, and smoking status) will be collected from the electronic medical record.
- Conditions
- Robotic Surgery, Pneumoperitoneum
- Being tested
- AirSeal Robotic Solution, Standard-pressure pneumoperitoneum (15 mmHg)
- Keywords
- robotic surgery, low-pressure pneumoperitoneum, recovery time, pain, pneumoperitoneum
- Medical subject headings
- Pneumoperitoneum, Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AirSeal Robotic SolutionDevice
The experimental intervention is low-pressure pneumoperitoneum at 8 mmHg using the AirSeal Robotic Solution device.
The AirSeal Robotic Solution (CONMED Corporation) is an FDA 510(k)-cleared carbon dioxide insufflation device that is indicated for use in robotic-assisted surgery. It consists of a console, tri-lumen filtered tube set, and access ports that function as valveless trocars.
The console of the device is mounted on a cart and regulates carbon dioxide flow and smoke evacuation by continuously measuring the intra-abdominal pressure. The trilumen filtered tube set carries carbon dioxide to the abdomen, transmits pressure information back to the console, and returns gas from the abdomen for smoke evacuation and filtration. These features allow for the device to operate in the "AirSeal" mode, whereby the pressure within the abdomen is effectively kept constant. The valveless trocars are access ports for the minimally invasive tools to enter the abdominal cavity.
Standard-pressure pneumoperitoneum (15 mmHg)Other
The control intervention is standard-pressure pneumoperitoneum set at a pressure of 15 mmHg. This will be delivered using the operating room's conventional valved-trocar carbon dioxide insufflator.
| Study group | Role | What they receive |
|---|---|---|
| Low-pressure pneumoperitoneum (AirSeal) | Experimental | Participants who are assigned to this arm will receive 8 mmHg pneumoperitoneum using the AirSeal Robotic Solution device.
The AirSeal Robotic Solution device is a FDA 510(k)-cleared carbon dioxide insufflation platform with valveless trocar technology that helps to maintain stable intra-abdominal pressure during surgery. Receives: Device: AirSeal Robotic Solution |
| Standard-pressure pneumoperitoneum | Active comparator | Participants who are assigned to this arm will receive 15 mmHg pneumoperitoneum using the conventional insufflation machine at New York-Presbyterian/Weill Cornell Medical Center. Receives: Other: Standard-pressure pneumoperitoneum (15 mmHg) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Average post-anesthesia care unit (PACU) length of stay in minutes from PACU admission to PACU discharge order
The PACU is the area where participants recover from anesthesia after surgery. The PACU recovery time will be computed in minutes as the interval between the documented PACU arrival timestamp and the documented PACU discharge-order timestamp which will both be abstracted from the institutional electronic medical record.
The discharge-order timestamp represents the clinical decision that the participant is fit to leave the PACU and is therefore not confounded by factors such as transport delays.
Measured: From PACU arrival (5 minutes post-surgery) to PACU discharge-order (1 to 4 hours post-surgery)
Secondary outcomes (12)
Average numeric rating scale (NRS) pain score (0-10) at PACU admission
Postoperative pain intensity is measured using a verbally administered numeric rating scale (NRS) ranging from 0 to 10.
0 indicates no pain while 10 indicates the worst pain that the participant can imagine or has experienced. The score will be recorded as an integer.
The pain scores will be taken from the participants within 5 minutes of documented PACU arrival.
Measured: PACU arrival (5 minutes post-surgery)
Average numeric rating scale (NRS) pain score (0-10) at PACU discharge
Postoperative pain intensity is measured using a verbally administered numeric rating scale (NRS) ranging from 0 to 10.
0 indicates no pain while 10 indicates the worst pain that the participant can imagine or has experienced. The score will be recorded as an integer.
The pain scores will be taken from the participants within 10 minutes of PACU discharge order time stamp.
Measured: PACU discharge (1-4 hours post-surgery)
Average numeric rating scale (NRS) pain score (0-10) at post-operative day 1 (POD1)
Postoperative pain intensity is measured using a verbally administered numeric rating scale (NRS) ranging from 0 to 10.
0 indicates no pain while 10 indicates the worst pain that the participant can imagine or has experienced. The score will be recorded as an integer.
The pain scores will be taken from the participants on POD1 between the hours of 08:00 and 12:00. If the participant is discharged, a telephone call will be made during those hours.
Measured: Post-operative day 1 (24 hours after surgery)
Average numeric rating scale (NRS) pain score (0-10) at post-operative day 3 (POD3)
Postoperative pain intensity is measured using a verbally administered numeric rating scale (NRS) ranging from 0 to 10.
0 indicates no pain while 10 indicates the worst pain that the participant can imagine or has experienced. The score will be recorded as an integer.
The pain scores will be taken from the patients on POD3 between the hours of 08:00 and 12:00. If the participant is discharged, a telephone call will be made during those hours.
Measured: Post-operative day 3 (72 hours after surgery)
Average morphine milligram equivalents (MME) in the post-anesthesia care unit (PACU)
Cumulative opioid consumption will be measured using morphine milligram equivalents (MME) which will convert all administered opioids regardless of agent or route of administration to an equivalent amount of oral morphine using standard conversion factors.
Opioid dosage data will be abstracted from the electronic medical record. The total MME administered between the PACU arrival timestamp and the documented PACU discharge-order timestamp will be recorded.
A lower cumulative MME indicates less opioid requirements.
Measured: PACU arrival to PACU discharge (1-4 hours post-surgery)
Average morphine milligram equivalents (MME) over the first 24-hour post-operative period
Cumulative opioid consumption will be measured using morphine milligram equivalents (MME) which will convert all administered opioids regardless of agent or route of administration to an equivalent amount of oral morphine using standard conversion factors.
Opioid dosage data will be abstracted from the electronic medical record. The total MME administered within the first 24 hours after surgery will be recorded.
A lower cumulative MME indicates less opioid requirements.
Measured: Post-operative day 1 (24 hours after surgery)
Proportion of participants experiencing postoperative nausea or vomiting in the post-anesthesia care unit (PACU)
Postoperative nausea or vomiting is defined as any event of nausea or emesis. Episodes will be abstracted from the electronic medical record and corroborated by asking the patient.
Events will be recorded during the PACU stay
Measured: PACU arrival to PACU discharge (1-4 hours post-surgery)
Proportion of participants experiencing postoperative nausea or vomiting on post-operative day 1 (POD1)
Postoperative nausea or vomiting is defined as any event of nausea or emesis. Episodes will be abstracted from the electronic medical record and corroborated by asking the patient.
Events will be recorded on POD1
Measured: Post-operative day 1 (24 hours after the surgery)
Proportion of participants experiencing postoperative nausea or vomiting on post-operative day 3 (POD3)
Postoperative nausea or vomiting is defined as any event of nausea or emesis. Episodes will be abstracted from the electronic medical record and corroborated by asking the patient.
Events will be recorded on POD3
Measured: Post-operative day 3 (72 hours after the surgery)
Proportion of participants who require intra-operative conversion from robotic-assisted surgery to open surgery
Conversion events will be abstracted from the operative note posted on the electronic medical record.
Measured: During the surgery (about 60 to 240 minutes)
Proportion of participants with clinical or radiographic subcutaneous emphysema
Cases will be identified by intraoperative inspection of the abdominal wall during the procedure, clinical examination during the PACU stay, and any postoperative imaging that is clinically obtained.
Measured: From start of surgery to PACU discharge (1-4 hours after surgery)
Proportion of participants who sustained intraoperative pressure elevation (defined as sustained increase to ≥12 mmHg for ≥10 minutes in the AirSeal arm)
Pressure measurements will be obtained from the AirSeal console and elevations will be recorded regardless of reason.
Measured: During the surgery (about 60 to 240 minutes)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jul 2026
- Study start30 Jul 2026
- Primary completionJan 2027 (estimated)
- Study completionFeb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Robotic SurgeryStudies of the same condition, open and under way.
- More trials run by Weill Medical College of Cornell UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomization will be performed using a computer-generated permuted block sequence pre-loaded into REDCap with allocation concealed until the day of surgery. Allocation will be blinded to participants and outcome assessors. Surgical staff cannot be blinded to allocation for safety reasons.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Weill Medical College of Cornell University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Cheguevara Afaneh, MD, Principal investigator, New York-Presbyterian/Weill Cornell Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07710352
- Sponsor's protocol ID
- 26-05030301
- Status last verified
- Aug 2026
- First submitted
- 13 Jul 2026
- Last updated
- 20 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison Between Low Pressure (8 mmHg) AirSeal Insufflation vs Standard Pressure (15 mmHg) Pneumoperitoneum on Postoperative Recovery in Minimally Invasive Robotic Surgery: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07710352
- Acronym / sponsor ID
- 26-05030301
- Conditions
- Robotic Surgery, Pneumoperitoneum
- Keywords
- robotic surgery, low-pressure pneumoperitoneum, recovery time, pain, pneumoperitoneum
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Weill Medical College of Cornell UniversityUniversity, hospital or other
- Study start
- 30 Jul 2026 (actual)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Feb 2027 (estimated)
- First posted
- 17 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
During surgery that is done using a robot, the surgeon needs to put carbon dioxide gas into the belly to lift the belly wall. This is done so the surgeon can adequately see all the body organs and operate safely. Many surgeons currently use a standard pressure of 15 mmHg (a unit to measure pressure). However, many patients find the use of this pressure to be painful after surgery. New research has shown that using a lower pressure with a device called "AirSeal" can safely reduce pain and lead to faster recovery after surgery.
The goal of this clinical trial is to learn if using a lower gas pressure with the AirSeal device during robotic surgery, compared to standard gas pressure with conventional devices, helps adults feel less pain and recover faster.
The study includes adults aged 18 or older having robotic at New York-Presbyterian Hospital/Weill Cornell Medical Center.
The main questions this clinical trial aims to answer are:
- Does using lower gas pressure shorten the time people spend in the recovery room after surgery?
- Does using lower gas pressure lead to less pain and reduce the need for pain medicine after surgery?
Detailed description
Robotic surgeries require the use of pneumoperitoneum, which is a standard of care as it creates a working environment to utilize minimally invasive tools to accomplish surgical procedures. However, there is no uniform standard pressure (usually between 12-15 mmHg). Moreover, maintaining the same pressure throughout the procedure can be inconsistent at best. Elevations in pneumoperitoneum cause significant stretch to the peritoneum which results in significant postoperative pain, longer post-anesthesia care unit (PACU) stay times, and higher opioid consumption. These effects are amplified to a higher degree in patients with severe obesity. If the pressures can be maintained and set to lower levels, then patients may have the opportunity to recover in the immediate postoperative period.
The AirSeal Robotic Solution (CONMED Corporation) is an FDA 510(k)-cleared carbon dioxide insufflation device that is indicated for use in robotic-assisted surgery.
This study is a prospective, single-center, single-blind, double-arm parallel-group randomized controlled trial that aims to determine if the use of low-pressure (8 mmHg) AirSeal insufflation, compared to standard-pressure (15 mmHg) pneumoperitoneum, provides superior patient outcomes in terms of post-operative recovery time and convalescence.
During the preoperative evaluation, participants will be consented and enrolled into the trial. Participants will then be randomly allocated to either low-pressure AirSeal insufflation (8 mmHg) or standard-pressure pneumoperitoneum (15 mmHg). Patients and outcome assessors will be blinded to allocation; however, for safety purposes, the operating surgeon and anesthesiologist cannot be blinded.
Intraoperative data (including operation time, estimated blood loss, abdominal pressure, and pressure deviations) will be recorded. Participant data related to comorbidities (i.e. body mass index, American Society of Anesthesiologists physical status, hypertension, diabetes, obstructive sleep apnea, chronic obstructive pulmonary disease/asthma, and smoking status) will be collected from the electronic medical record.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- Randomization will be performed using a computer-generated permuted block sequence pre-loaded into REDCap with allocation concealed until the day of surgery. Allocation will be blinded to participants and outcome assessors. Surgical staff cannot be blinded to allocation for safety reasons.
| Arm | Type | Receives |
|---|---|---|
| Low-pressure pneumoperitoneum (AirSeal) | Experimental | Device: AirSeal Robotic SolutionParticipants who are assigned to this arm will receive 8 mmHg pneumoperitoneum using the AirSeal Robotic Solution device. The AirSeal Robotic Solution device is a FDA 510(k)-cleared carbon dioxide insufflation platform with valveless trocar technology that helps to maintain stable intra-abdominal pressure during surgery. |
| Standard-pressure pneumoperitoneum | Active comparator | Other: Standard-pressure pneumoperitoneum (15 mmHg)Participants who are assigned to this arm will receive 15 mmHg pneumoperitoneum using the conventional insufflation machine at New York-Presbyterian/Weill Cornell Medical Center. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Aged 18 years or older
- Scheduled to undergo robotic-assisted surgery at New York-Presbyterian/Weill Cornell Medical Center
- American Society of Anesthesiologists physical status I-III
- Able to understand and provide written informed consent in English
Key exclusion criteria (6 listed)
- American Society of Anesthesiologists physical status IV or higher (i.e. a severe systemic disease that is a constant threat to life such as decompensated heart failure)
- Chronic opioid use (≥30 morphine milligram equivalents per day for ≥30 days within the past 6 months)
- Current pregnancy
- Inability to understand and provide informed consent in English
- Inability to provide informed consent due to cognitive impairment or other conditions impacting decision-making capacity
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AirSeal Robotic SolutionThe experimental intervention is low-pressure pneumoperitoneum at 8 mmHg using the AirSeal Robotic Solution device. The AirSeal Robotic Solution (CONMED Corporation) is an FDA 510(k)-cleared carbon dioxide insufflation device that is indicated for use in robotic-assisted surgery. It consists of a console, tri-lumen filtered tube set, and access ports that function as valveless trocars. The console of the device is mounted on a cart and regulates carbon dioxide flow and smoke evacuation by continuously measuring the intra-abdominal pressure. The trilumen filtered tube set carries carbon dioxide to the abdomen, transmits pressure information back to the console, and returns gas from the abdomen for smoke evacuation and filtration. These features allow for the device to operate in the "AirSeal" mode, whereby the pressure within the abdomen is effectively kept constant. The valveless trocars are access ports for the minimally invasive tools to enter the abdominal cavity. | Device | Low-pressure pneumoperitoneum (AirSeal) |
| Standard-pressure pneumoperitoneum (15 mmHg)The control intervention is standard-pressure pneumoperitoneum set at a pressure of 15 mmHg. This will be delivered using the operating room's conventional valved-trocar carbon dioxide insufflator. | Other | Standard-pressure pneumoperitoneum |
Primary outcome
Average post-anesthesia care unit (PACU) length of stay in minutes from PACU admission to PACU discharge order
Time frame: From PACU arrival (5 minutes post-surgery) to PACU discharge-order (1 to 4 hours post-surgery)
The PACU is the area where participants recover from anesthesia after surgery. The PACU recovery time will be computed in minutes as the interval between the documented PACU arrival timestamp and the documented PACU discharge-order timestamp which will both be abstracted from the institutional electronic medical record. The discharge-order timestamp represents the clinical decision that the participant is fit to leave the PACU and is therefore not confounded by factors such as transport delays.
12 secondary outcomes
Average numeric rating scale (NRS) pain score (0-10) at PACU admission
Time frame: PACU arrival (5 minutes post-surgery)
Average numeric rating scale (NRS) pain score (0-10) at PACU discharge
Time frame: PACU discharge (1-4 hours post-surgery)
Average numeric rating scale (NRS) pain score (0-10) at post-operative day 1 (POD1)
Time frame: Post-operative day 1 (24 hours after surgery)
Average numeric rating scale (NRS) pain score (0-10) at post-operative day 3 (POD3)
Time frame: Post-operative day 3 (72 hours after surgery)
Average morphine milligram equivalents (MME) in the post-anesthesia care unit (PACU)
Time frame: PACU arrival to PACU discharge (1-4 hours post-surgery)
Average morphine milligram equivalents (MME) over the first 24-hour post-operative period
Time frame: Post-operative day 1 (24 hours after surgery)
Proportion of participants experiencing postoperative nausea or vomiting in the post-anesthesia care unit (PACU)
Time frame: PACU arrival to PACU discharge (1-4 hours post-surgery)
Proportion of participants experiencing postoperative nausea or vomiting on post-operative day 1 (POD1)
Time frame: Post-operative day 1 (24 hours after the surgery)
Proportion of participants experiencing postoperative nausea or vomiting on post-operative day 3 (POD3)
Time frame: Post-operative day 3 (72 hours after the surgery)
Proportion of participants who require intra-operative conversion from robotic-assisted surgery to open surgery
Time frame: During the surgery (about 60 to 240 minutes)
Proportion of participants with clinical or radiographic subcutaneous emphysema
Time frame: From start of surgery to PACU discharge (1-4 hours after surgery)
Proportion of participants who sustained intraoperative pressure elevation (defined as sustained increase to ≥12 mmHg for ≥10 minutes in the AirSeal arm)
Time frame: During the surgery (about 60 to 240 minutes)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Robotic Surgery
RecruitingPhase 2
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
Head and Neck Cancer, Head and Neck Squamous Cell Cancer
RecruitingObservational study
GENERATE - Next GENERATion of GynEcological Surgery - Robotic Assisted Surgery in Gynecological Indications
GYN Disorders
Not yet recruitingObservational study
A Study Comparing Single-Port and Multi-Port Robot-Assisted Surgery in Patients With Prostate or Kidney (Renal) Cancer
Prostate Cancer, Renal Cancer
Active, not recruiting
Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)
Bladder Cancer, Prostate Cancer
Not yet recruitingObservational study
Fluid Responsiveness in Laparoscopic Surgery: End-Expiratory Occlusion Test Versus Mini-Fluid Challenge
Fluid Responsiveness, Laparoscopic Surgery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Cheguevara Afaneh, MD principal investigator
New York-Presbyterian/Weill Cornell Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing AirSeal Robotic Solution and Standard-pressure pneumoperitoneum (15 mmHg) in people with Robotic Surgery and Pneumoperitoneum, run by Weill Medical College of Cornell University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Cheguevara Afaneh, MD ((646) 962-8462, cha9043@med.cornell.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Average post-anesthesia care unit (PACU) length of stay in minutes from PACU admission to PACU discharge order (time frame: From PACU arrival (5 minutes post-surgery) to PACU discharge-order (1 to 4 hours post-surgery)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2026.